Revision 14 for 'Breast implant associated - anaplastic large cell lymphoma'All Revisions
Breast Implant Associated - Anaplastic Large Cell Lymphoma (BIA-ALCL)
Breast Implant Associated - Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare from of T-cell lymphoma which has primarily been associated with textured breast implants.
Patients typically present with development of a late onset fluid collection surrounding the implant or less commonly after identification of a breast or axillary mass. Cases have been reported as early as 1 year after surgery and as late as 37 years post augmentation mammoplasty. The average time to clinical presentation is reported to be approximately 10 years post breast augmentation.
The exact causative etiology has not been confirmed, however it is widely postulated that it is likely multifactorial in nature and due to a combination of factors including chronic inflammation, implant texturing and a subclinical infective pathology related to biofilm. The end result of the multiple insults malignant transformation of T-cells which are anaplastic lymphoma kinase negative and CD30 positive.
Sonography typically demonstrates a fluid collection between the breast implant and the capsule. Septa are often appreciated during the study. Ultrasound is reported to have a sensitivity of 84% and specificity of 75% for detecting effusions and a sensitivity of 46% and specificity of 100% for detecting a BIA-ALCL mass.
BIA-ALCL related effusions and masses may be appreciated on MRI. Capsular enhancement has also been reported in a small number of cases as has evidence of implant rupture.
One documented protocol for MR imaging in BIA-ALCL utilized the following sequences:
- T1-weighted spin echo
- T2-weighted fat suppressed fast spin echo
- Dynamic contrast enhanced T1-weighted 3D fat surpassed fast spoiled gradient echo at 2 minute intervals pre and post administration of intravenous gadopentetate dimeglumine.
- Delayed contrasted enhanced T1-weighted 3D fat-suppressed fast spoiled gradient echo
Lesions typically demonstrate fludeoxyglucose (18F) avidity on positron emission tomography and the modality may be utilized to assess for systemic disease.
In the initial setting, ultrasound guided fine needle aspiration of the effusion surrounding the breast implant is undertaken. Cytology is subsequently used to assist with confirming the diagnosis. A finding of atypical cells with ≥10% expressing CD30 is said to favor a diagnosis of BIA-ALCL.
Multidisciplinary management including radiology, hematology, oncology, plastic surgery and or surgical oncology input forms the basis of management.
Management typically involves a complete en-bloc capsulectomy and explantation fo the prosthesis with patients subsequently receiving some form of chemotherapy and or radiotherapy depending on the extent of disease.
- Liquified hematoma
- Primary breast cancer
The first case of BIA-ALCL was reported by Keech and Creech in the Journal of Plastic & Reconstructive Surgery in 1997.